Duration and clinical relevance of postantibiotic effect in relation to the dosing interval by Hollander, J.G. (Jan) den et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/98/$04.0010
Apr. 1998, p. 749–754 Vol. 42, No. 4
Copyright © 1998, American Society for Microbiology
Duration and Clinical Relevance of Postantibiotic Effect in
Relation to the Dosing Interval
JAN G. DEN HOLLANDER,1* KURT FUURSTED,2 HENRI A. VERBRUGH,1 AND JOHAN W. MOUTON1
Department of Medical Microbiology and Infectious Diseases, University Hospital Rotterdam, Dijkzigt, Rotterdam,
The Netherlands,1 and Department of Clinical Microbiology, Statens Serum Institut, Copenhagen, Denmark2
Received 28 January 1997/Returned for modification 27 July 1997/Accepted 23 December 1997
The influence of half-life on the postantibiotic effect (PAE) of tobramycin against Pseudomonas aeruginosa
and Staphylococcus aureus was investigated during one dosing interval. Tobramycin half-lives of 0.5 to 2.5 h
were simulated in an in vitro model, and the PAE was determined by an enzymatic inactivation method at
different time points, i.e., when the tobramycin concentrations were 203, 53, and 13 the MIC. At the time
point during therapy when the tobramycin concentrations had declined to 13 the MIC, at a tobramycin
half-life of 0.5 h, the times of the PAEs were approximately 0.7 and 1.7 h for P. aeruginosa and S. aureus,
respectively, and the PAE disappeared completely at half-lives corresponding to those found in humans (i.e.,
2 to 2.5 h). The PAE itself cannot be fully explained by the presence of free intrabacterial tobramycin or the
emergence of resistant subpopulations. The explanation for the disappearance of the PAE during the dosing
interval may therefore be explained by the repair of sublethal damage. Since the standard method of deter-
mining the PAE in animal models is somewhat different from the method used for measurement of the PAE in
vitro, the conditions under which the PAE is measured in vivo were also simulated in the in vitro model. This
resulted in PAEs longer than those found by the standard method of obtaining in vitro PAE measurements. We
conclude that the PAE of tobramycin, as determined by conventional in vitro methods, has virtually no clinical
importance. PAEs determined in vivo may have some clinical relevance, but they are probably primarily caused
by sub-MIC effects.
The clinical relevance of the postantibiotic effect (PAE)
determined in vitro remains questionable. The main problem is
that the PAE is measured as delayed bacterial growth after a
short on-off exposure to an antibiotic for 1 or 2 h (4). Such
exposure does not reflect the situation in humans under clin-
ical conditions, where bacteria are exposed to antibiotic con-
centrations that decline only slowly over time, with half-lives of
up to several hours. Nevertheless, the PAE has been used to
support the lengthening of the dosing interval for aminoglyco-
sides (14, 15, 20, 22), since it is assumed that the PAE would
significantly delay bacterial regrowth after the antibiotic con-
centration falls below the MIC (2).
Recently, we showed that the PAE completely disappeared
during one interval of dosing with tobramycin simulated in an
in vitro pharmacokinetic model (5). The PAE determined at
the peak concentration (203 the MIC) correlated well with the
PAE measured under standard conditions, but it declined to
zero at the end of a dosing interval. There are several expla-
nations for the PAE and the disappearance thereof. The PAE
itself can be explained by several hypotheses, e.g., sublethal
damage in the bacteria that is due to antibiotic exposure and
that needs to be repaired before the normal growth rate re-
turns. Another explanation might be a growth retardation due
to free tobramycin which remains inside the bacteria and which
is not removed during the washout phase of the PAE experi-
ment. On the other hand, the disappearance of the PAE, which
was observed during one interval of dosing with tobramycin
(5), may be a result of the outgrowth of resistant subpopula-
tions of bacteria. Alternatively, the phenomenon may be due to
slow diffusion of tobramycin out of the bacteria or may be a
result of a fast repair process in the bacteria. These last pro-
cesses may happen in the foci of slowly declining antibiotic
concentrations from a dosing interval in vivo, while the fast
washout of tobramycin during the determination of the PAE in
vitro may be too short for these processes to start and have an
effect. The PAE may thus be an in vitro phenomenon that does
not occur in vivo.
Thus, the most striking difference between the PAE deter-
mination in vitro and in vivo is the fast elimination of the
antibiotic (i.e., a very short half-life) during in vitro experi-
ments. In order to study the effect of the half-life on the PAE
of tobramycin, we determined the PAE during one interval of
dosing with tobramycin in an in vitro pharmacokinetic model,
simulating tobramycin half-lives in the range of 0.5 to 2.5 h.
The PAE was determined at three time points during the
interval corresponding to tobramycin concentrations of 203
the MIC, 53 the MIC, and 13 the MIC. Furthermore, we
looked for the emergence of resistant subpopulations of bac-
teria during these PAE determinations, and the hypothesis of
the diffusion process was investigated. Finally, to determine
whether the larger PAE found in vivo compared to that found
in vitro (3) is due to differences in the methods used, the
conditions of both methods were simulated in the in vitro
model.
(This work was presented at the 37th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy, Toronto,
Ontario, Canada, 28 September to 1 October 1997 [6a].)
MATERIALS AND METHODS
Bacterial strains and media. The strains used were Staphylococcus aureus
ATCC 29213 and Pseudomonas aeruginosa ATCC 27853. Mueller-Hinton broth
(Difco, Amsterdam, The Netherlands) supplemented with Ca21 (25 mg/liter)
and Mg21 (12.5 mg/liter) was used in all experiments (MHBs). All bacterial
samples were plated on Trypticase Soy Agar (TSA; Oxoid, Basingstoke, Hamp-
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shire, England). The MIC of tobramycin was 0.5 mg/liter for both the S. aureus
strain and the P. aeruginosa strain, as determined by a standard macrodilution
method with MHBs (19).
Antibiotic. Tobramycin was provided as a solution with a concentration of 10
g/liter (Eli Lilly & Company, Nieuwegein, The Netherlands). Tobramycin con-
centrations were assayed by a fluorescence polarization immunoassay with a
TDxFLx instrument (Abbott Diagnostic Division, Amstelveen, The Nether-
lands), which had concentration detection range of 0 to 10 mg/liter and a
coefficient of variation of ,6%.
Pharmacokinetic model. The pharmacokinetic model used in this study was
previously described in detail (18). Briefly, a two-compartment model consisting
of one central compartment and four peripheral compartments including dis-
posable dialyzer units (ST23; Baxter, Utrecht, The Netherlands) was used. The
bacteria were exposed in the peripheral compartments to a changing antibiotic
concentration that mimicked the pharmacokinetics of tobramycin; the pharma-
cokinetic profile depended on the half-life chosen for a given experiment.
A volume of 150 ml of a logarithmic-phase culture of S. aureus or P. aeruginosa
(approximately 107 CFU/ml) was injected into the peripheral compartments. At
time zero a total dose of 15 mg of tobramycin was infused into the central
compartment over 1 h with an infusor (Braun, Melsungen AG, Germany); this
resulted in a peak concentration of approximately 10 mg/liter at 1 h. During the
first hour (the infusion time) the half-life was adjusted to 2 h; thereafter, the
half-life of tobramycin was set to 0.5, 1, 1.5, 2, or 2.5 h, as indicated. These
different half-lives resulted in a time above the MIC (T.MIC) in a range of 3.1 to
11.9 h and an area under the concentration-time curve (AUC) of 12.3 to 40.2 mg z
h/liter.
Killing kinetics. To determine the tobramycin concentration and bacterial
CFU, samples were taken from each peripheral compartment at time zero, 30
min, and 1 h and at time points when the tobramycin concentrations were 53 the
MIC and 13 the MIC. To determine the killing rate, samples were washed two
times with cold phosphate-buffered saline (PBS), serially diluted 10-fold in cold
PBS, and plated onto TSA plates for colony count determination.
PAE determination. To determine the PAE at different concentrations, sam-
ples of 10 ml were taken at the peak concentration (203 the MIC) and at the
time points corresponding to tobramycin concentrations of 53 the MIC and 13
the MIC. An enzymatic method for the inactivation of tobramycin was used (6).
Briefly, 10 ml of each sample was added to a freshly prepared solution of
tobramycin-acetylating enzyme AAC (3)-II (16) and acetyl coenzyme A, result-
ing in the inactivation of tobramycin within 5 min. A volume of 5 ml of this
solution was immediately placed on ice for one night, to allow free intrabacterial
tobramycin to diffuse out of the bacteria, where it would be inactivated by the
enzymes. The rate of regrowth in the remaining 5 ml was determined, and the
PAE was defined as PAE 5 T 2 C, where T is the time required for the numbers
of CFU in the test culture to increase 1 log10 above the count immediately after
drug removal and C is the corresponding time for the controls (4). Samples were
taken from the PAE regrowth cultures at 0, 1, 2, 3, 4, and 5 h and serially diluted
in cold PBS. Volumes of 0.25 and 0.1 ml were plated onto TSA for the undiluted
samples and for the samples with other dilutions, respectively, and the plates
were incubated at 37°C overnight for P. aeruginosa or 48 h for S. aureus. The
undiluted samples were also plated onto Iso-Sensitest agar plates (Oxoid), con-
taining tobramycin at concentrations of 0.5, 1, 2, 4, and 8 mg/liter to detect the
presence of resistant subpopulations. Control growth curves were determined in
the same in vitro pharmacokinetic model, but without the addition of tobramy-
cin. Control samples were taken at 0, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 h and
in the tests with tobramycin at time points when the tobramycin concentrations
were 53 the MIC and 13 the MIC. The control samples were diluted in MHBs
(at 37°C) until the inoculum had the same starting numbers of CFU per milliliter
as the test strain at this time. A volume of 10 ml of this control inoculum was
treated as described above for the test cultures. All samples that had been placed
on ice overnight were quickly brought to 37°C as described previously (7, 8), and
regrowth experiments were performed as described above. All experiments were
performed in duplicate on at least two separate occasions.
Simulation of in vivo PAE in mice with renal impairment. To study the
differences between the PAE determined in vitro versus that determined in vivo,
experimental conditions were simulated as described by Craig et al. (3). Briefly,
in their experiments renal impairment was induced in neutropenic mice, result-
ing in an amikacin half-life of 93.3 to 121 min, thus approaching the pharmaco-
kinetics in humans. For the in vitro simulation of the pharmacokinetics in such
mice, the experiments were started as described above, and after 1 h the half-life
was adjusted to 1.5, 2.0, or 2.5 h. During these experiments no enzymatic inac-
tivation of the tobramycin was used, since in the in vivo experiments the PAE is
defined as the time that the culture needs to grow 1 log10 after the antibiotic
concentration declines below the MIC (13). Samples were taken from the pe-
ripheral compartments of the in vitro model at 0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 24,
and 28 h and at the time point when the tobramycin concentration was 13 the
MIC. To determine the numbers of CFU per milliliter, the samples were washed
twice in cold PBS, diluted serially 10-fold in cold PBS, and plated onto TSA
plates. Control growth curves were determined with the model, and at the same
time points when the test cultures had a tobramycin concentration of 13 the
MIC, samples were taken and diluted in prewarmed MHBs until the starting
inoculum was equal to the starting inoculum of the test culture at that time point,
as described above. Regrowth of the control was determined outside the model
in a test tube containing 10 ml. The PAE was determined as described by
Gudmundsson et al. (13) by the formula PAE 5 T 2 C 2 M, where M represents
the time that the concentration in serum exceeds the MIC.
Statistics. The peak concentrations, the half-lives, and the PAE data were
analyzed by the Tukey-Kramer multiple comparisons test, one-way analysis of
variance, and a test for linear trend between column means with the Instat
statistics program (12). A P value of #0.05 (two tailed) was considered signifi-
cant. The correlation between the PAE and other parameters was determined by
the parametric correlation test of Pearson.
RESULTS
Antibiotic concentrations and pharmacokinetics. The ob-
served peak concentration (mean 6 standard error of the
mean [SEM]) and the concentrations at time points when the
tobramycin concentrations were 53 the MIC and 13 the MIC
were 10.6 6 0.3, 2.8 6 0.1, and 0.7 6 0.1 mg/liter, respectively.
The tobramycin half-lives (mean 6 SEM) during the various
experiments were 0.6 6 0.1, 1.1 6 0.1, 1.7 6 0.1, 2.2 6 0.1, and
2.6 6 0.1 h.
Killing kinetics. Killing and regrowth of P. aeruginosa and S.
aureus were determined in the pharmacokinetic model during
all experiments. A representative example of the killing and
regrowth curves for both strains exposed to tobramycin with a
half-life of 1.5 h is shown in Fig. 1. Figure 1 also shows exam-
ples of a control growth curve and the control regrowth curve.
If the control regrowth curve is compared with the control
growth curve in the model, it seems to have a short lag phase
before regrowth begins exponentially.
FIG. 1. Representative curves for control growth (F), control regrowth (E),
killing (n), and regrowth after killing (h) of P. aeruginosa and S. aureus deter-
mined during all experiments with the pharmacokinetic model. For these curves
the samples for PAE measurement were taken when the tobramycin concentra-
tion was 53 the MIC during the simulation with a half-life of 1.5 h. PAE can be
determined as PAE 5 T 2 C, as described by Craig and Gudmundsson (4) (see
text for details).
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PAE determination. A summary of all mean 6 SEM PAEs
determined in the various experiments is given in Fig. 2. The
mean 6 SEM PAEs for P. aeruginosa and S. aureus determined
at the peak concentration (203 the MIC) were 2.0 6 0.7 and
1.8 6 0.5 h, respectively, which are comparable to those pub-
lished previously (5), and were not significantly different be-
tween the different experiments. The PAEs for P. aeruginosa at
a tobramycin concentration of 53 the MIC depended on the
tobramycin half-life chosen. A significantly decreasing linear
trend (P , 0.0001) was found, from a mean 6 SEM PAE of
2.0 6 0.2 h to one of 0.8 6 0.3 h for half-lives of 0.5 and 2.5 h,
respectively. At a concentration of 13 the MIC, the PAE was
about 0.7 h for half-lives of 0.5 to 2.0 h but completely disap-
peared if the tobramycin half-life was set at 2.5 h (Fig. 2). In
experiments with S. aureus and a tobramycin concentration of
53 the MIC, the PAEs showed no significant difference for
half-lives of 0.5, 1, and 1.5 h, but a significant decrease in the
PAEs was observed for half-lives of 2 and 2.5 h (P , 0.001). At
a concentration of 13 the MIC the PAEs for S. aureus de-
creased from 1.7 6 0.5 to 0.1 6 0.2 h, resulting in a significant
linear trend (P , 0.0001). The data presented in Fig. 2 also
indicate that the PAEs for both P. aeruginosa and S. aureus
decline during a dosing interval. For P. aeruginosa the PAE was
a significant linear declining trend (0.0001 , P # 0.01) during
the dosing interval for half-lives of 1.0 to 2.5 h. For S. aureus
the PAE also decreases during the dosing interval, but a sig-
nificant linear decrease in PAE is observed only for half-lives
of 2.0 and 2.5 h (P 5 0.004 and P , 0.0001, respectively).
The linear declining trend seen with an increase in the half-
life is also shown by the good correlations between the AUC
and the PAE. The AUC determined for the time period until
the concentration declines below the MIC correlates well with
the PAE at 13 the MIC for S. aureus (r 5 20.99; P , 0.001)
and with the PAE at 53 the MIC for P. aeruginosa (r 5 0.90;
P 5 0.039).
PAE determination after incubation on ice. To study the
effect of free intrabacterial tobramycin, the PAE was deter-
mined after an overnight incubation on ice, and the DPAE
(DPAE 5 direct PAE 2 PAE after incubation on ice) was
calculated for P. aeruginosa and S. aureus. The overall DPAEs
(mean 6 SEM) were 0.3 6 0.5 h (P , 0.0001) and 0.3 6 0.4 h
(P , 0.0001) for P. aeruginosa and S. aureus, respectively,
indicating a slight but significantly lower PAE when the PAE
was determined after incubation on ice. Differentiation of the
DPAEs determined when the concentration was at its peak
versus those determined when the concentrations were at 53
the MIC and 13 the MIC indicated that the effect of additional
incubation on ice was mainly observed for the PAEs calculated
when the concentration was 53 the MIC (mean 6 SEM
DPAE 5 0.5 6 0.5 h for both P. aeruginosa and S. aureus).
Regrowth of resistant subpopulations. No resistant sub-
populations of P. aeruginosa were found during any of the
experiments. For S. aureus all samples showed growth on the
plates containing 0.5 and 1.0 mg of tobramycin per liter. How-
ever, the samples used to generate control growth curves and
plated on the same plates also showed the same growth on
these plates. This would indicate that there may be a subpopu-
lation in the starting inoculum for which the MIC is slightly
higher. Another phenomenon, seen for S. aureus only, was the
growth of small colony variants. These colony types were visi-
ble only after incubation for 48 h at 37°C. The MIC of tobra-
mycin for these small colonies by an E-test (AB-Biodisk, Solna,
Sweden) reached 2 to 4 mg/liter. The generation time in MHBs
at 37°C for the small colony variants showed a range of 55.0 to
60.3 min (n 5 4) compared to a generation time of 35 min for
the original test strain and for the large colony types after
FIG. 2. Mean 6 SEM PAEs determined with concentrations of 53 the MIC and 13 the MIC for P. aeruginosa and for S. aureus, respectively, during the simulation
with different half-lives (t1/2) of tobramycin.
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treatment (n 5 4). The DNAs of both the large and the small
colony types were typed by random amplification of polymor-
phic DNA (RAPD) by previously described protocols (23),
using RAPD 1, RAPD 7, and ERIC II as primers, to check
whether the small and large colony variants were genetically
identical. Since no variability in the amplification patterns was
observed, genetic differences between the two variants were
either small or absent.
Simulation of in vivo PAE in mice with renal impairment. A
representative example of a killing curve for P. aeruginosa,
combined with its growth curve, as determined in the pharma-
cokinetic model after one tobramycin dosing interval, is shown
in Fig. 3. These curves indicate the existence of a prolonged
regrowth time after the concentration has declined below the
MIC, resulting in long PAEs. The mean PAEs for the strains
determined during those simulation experiments are presented
in Table 1. These data were compared with the PAE values
determined when the concentration was at its peak (203 the
MIC) and at 13 the MIC, as determined during the experi-
ments described above. This shows a long PAE for Pseudomo-
nas, when simulating the in vivo circumstances, which is even
longer than the PAE determined at 203 the MIC. For both
strains the PAEs determined during the simulation of the in
vivo situation were longer than those determined with 13 the
MIC.
DISCUSSION
In a previous article we described the fact that the PAEs for
P. aeruginosa and S. aureus disappeared during one interval of
tobramycin dosing (5). However, the mechanism behind this
phenomenon was not clear. The phenomenon of the PAE can
be explained by several mechanisms. One is that sublethal
damage in the exposed but surviving bacteria needs to be
repaired before regrowth can start. It could also be that some
free tobramycin remains inside the bacteria and causes growth
retardation. The first explanation has been investigated by
others (1, 9, 10), and their results indicate that DNA, RNA,
and protein syntheses are all inhibited during exposure to
tobramycin. For Pseudomonas DNA and RNA syntheses re-
cover rapidly during the PAE phase and a large increase in
DNA synthesis is seen shortly before logarithmic regrowth
starts. In contrast, protein synthesis was inhibited throughout
the PAE phase and was resumed only after the bacteria were
again in the logarithmic phase of growth. The conclusions that
can be drawn from these observations could be that sublethal
damage is induced by tobramycin exposure, that the damage
needs time to be repaired, and that this time correlates with
the PAE. In an earlier observation, Gottfredsson et al. (11)
observed that tobramycin induced ultrastructural changes,
such as a pattern of dense nuclear material and peripheral
vacuoles, and that these changed during the PAE phase and
disappeared at the end of the PAE phase. This also indicates
that during the PAE phase repair mechanisms are working in
order to restore the normal growth rate.
The second possibility was partly investigated in this study by
determining the PAE after overnight incubation on ice, thus
allowing the free tobramycin inside the bacteria to diffuse out,
where it would be eliminated by the tobramycin-acetylating
enzymes (these enzymes also work at 0°C; data not shown).
Our results indicate that free intrabacterial tobramycin has
only a very minor effect. The largest effect of intrabacterial
tobramycin was seen in the experimental groups with the long-
est exposure time at a relatively high tobramycin concentration
(samples taken when the concentration was 53 the MIC). The
PAE thus seems to be predominantly due to sublethal damage,
reflected by inhibition of DNA, RNA, and protein syntheses
during the PAE phase, rather than due to free intrabacterial
tobramycin.
During the PAE determinations the control regrowth curves
seem to have a little lag phase, compared to the control growth
curve in the model, before exponential regrowth begins. This
may be explained by an inoculum effect due to dilution of the
control sample inoculum to the starting inoculum of the test
strains. Furthermore, at the time that the control samples were
taken the growth of the control was at the start of a stationary
phase, as indicated by the flattening of the control growth
curve. Another explanation for the growth rate difference may
be that the control growth was determined in the in vitro
model, in which the growth rate is slightly faster (unpublished
data), while the regrowth of the control was determined in a
tube.
The repair processes which take place during the PAE
period may well start at the time that the tobramycin concen-
trations are declining toward the MIC. The PAE in vitro is
normally determined after a short on-off exposure to the an-
tibiotic. This fast removal corresponds to a very short half-life
of the antibiotic, which may be too short for a repair process to
have started. By varying the half-life of tobramycin over a
range of 0.5 to 2.5 h, the time available for this repair process
FIG. 3. Representative control growth (E) and killing (h) curves for P. aeru-
ginosa in the in vitro model during a simulation of the pharmacokinetics of to-
bramycin in mice with renal impairment determined with a half-life of 2.5 h. PAE
was determined as PAE 5 T 2 C 2 M (13), where T is the time for the drug
exposed bacteria to grow 1 log10 CFU, C is the corresponding time for the
nonexposed control, and M is the time above the MIC.
TABLE 1. Comparison of tobramycin PAEs for P. aeruginosa
and S. aureus determined in vitro and during
simulation of in vivo PAE
Strain Half-life(h)
PAE (h)a
203 the MIC 13 the MIC Simulation ofin vivo PAE
P. aeruginosa 1.5 2.0 6 0.8 0.9 6 0.3 6.1 6 0.5
2.0 1.7 6 0.3 0.7 6 0.1 5.1 6 0.1
2.5 2.5 6 1.0 20.2 6 0.3 5.0 6 1.5
S. aureus 1.5 1.7 6 0.1 0.9 6 0.2 2.3 6 1.0
2.0 1.3 6 0.3 0.3 6 0.5 4.0 6 1.3
2.5 2.2 6 0.8 0.1 6 0.2 1.3 6 0.1
a Data are means 6 SEMs for two separate experiments.
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to start can be influenced. In the present study, the overall
effect of the half-life of tobramycin on the PAE is that the PAE
diminishes with increasing half-lives and finally disappears.
This indicates that for short half-lives, there is insufficient time
for this repair process to have an effect, so a PAE is still
present at the end of the dosing interval, while for longer
half-lives this time for repair is prolonged, resulting in the
disappearance of the PAE for a tobramycin half-life of 2 to
2.5 h or longer. The minimum half-life needed for the PAE is
clearly strain dependent, as would be expected. Stronger evi-
dence for the existence of repair mechanisms, which are active
during therapy and before the concentration declines below
the MIC, would be the observation of ultrastructural changes,
as mentioned earlier. For a further confirmation of our hy-
pothesis concerning the repair mechanism, our experiments
need to be combined with those of Gottfredson and colleagues
(9–11).
Shorter half-lives of tobramycin result in smaller AUCs and
a shorter T.MIC. The correlation seen between the increasing
half-life and the decline in the PAE can thus also be expressed
as a correlation between the AUC and PAE or the T.MIC and
PAE. Since only one dose was administered in these experi-
ments, it is not possible to determine the most important pa-
rameter for the disappearance of the PAE. Extrapolation of
the PAE data and the different AUCs by linear regression
analysis showed that the AUC had to be 40.4 mg z h/liter for the
PAE to become zero for S. aureus. However, linear regression
showed a reasonable fit only for S. aureus (r 5 0.86), so with
these data no unifying AUC could be determined to explain
the disappearance of the PAE during therapy. The same was
true for T.MIC and PAE.
The influence of the half-life on the disappearance of the
PAE seems contradictory for the PAE determined in vivo.
Craig et al. (3) showed in a mouse model that the PAE of
amikacin for P. aeruginosa was prolonged when they used a
half-life that was increased to 1.5 or 2.0 h instead of the normal
half-life of 18 to 32 min. In animal studies the PAE, by defi-
nition, is determined as delayed bacterial regrowth compared
to the growth of a control after the concentration of the anti-
biotic falls below the MIC. This is precisely the difference
between the methods for PAE determination in vivo and in
vitro. In the in vitro PAE test the delay in regrowth is measured
in antibiotic-free medium, while in vivo this delayed regrowth
is determined at sub-MICs. This may partly explain why the
PAE determined in vivo in mice with normal renal clearance is
longer than the PAEs measured in vitro, since this may be a
combination of a PAE and a postantibiotic sub-MIC effect
(PA-SME). Increasing the half-life in mice by inducing renal
impairment results in an even longer in vivo PAE (3). The
results presented above (i.e., longer PAEs in mice with renal
impairment) may thus be explained by the longer exposure of
microorganisms to sub-MICs and would better be described as
such. By simulation of both in vivo and in vitro PAE determi-
nation methods in our in vitro model, the roles of these sub-
MICs could be studied. With increasing half-lives in the in vitro
model, the PAE disappeared, while during simulation of the in
vivo PAE determination method, the PAE was still present and
was even longer than the PAE determined under standard in
vitro circumstances. The in vivo PAE thus correlates with the
PA-SME, as described by Odenholt-Tornqvist et al. (21). Fur-
thermore, that group of investigators recently showed (17) that
there is a significant difference between PAE and PA-SME for
Streptococcus pyogenes and penicillin when pharmacokinetics
in humans are simulated in an in vitro model.
Although the PAE values simulated in vivo approach the
values seen in animal models, they are not completely equal,
indicating that other environmental circumstances in vivo, such
as different generation times, may also be responsible for the in
vivo PAE. This should be investigated with different enrich-
ments of the medium used in vitro that would produce a
generation that approaches the in vivo generation time. Until
this has been investigated, the importance of these environ-
mental circumstances is not clear, but the sub-MICs during the
determination of the in vivo PAE seem to be of major impor-
tance.
Another explanation for the previous findings might be the
regrowth of resistant subpopulations. In the present study no
resistant subpopulations (or small colony variants) were found
for P. aeruginosa. This may be explained by the fact that the
agar plates containing P. aeruginosa samples were incubated
overnight and not for 48 h, as was done for S. aureus. This was
done because the P. aeruginosa colonies grew too fast for them
to be incubated longer than 24 h. For S. aureus small colony
variants were isolated, and for these isolates the MIC was
slightly increased, but the isolates were not resistant to tobra-
mycin. This appearance of a less susceptible subpopulation is
thus not likely to explain the disappearance of the PAE during
the dosing interval, since these small colony variants show an
increased generation time compared to that for the test strain;
the regrowth of the small colony types would thus result in a
prolongation rather than a disappearance of the PAE. There
was no correlation between the appearance of the small colony
variants and any of the variables during the experiments, such
as the half-life, AUC, T.MIC, sample time, or PAE value. The
fact that we did not find small colony variants for P. aeruginosa
is due to technical circumstances and is not in contradiction
with earlier findings (8).
The observations presented above indicate that the PAE of
tobramycin determined in vitro under standard conditions has
no clinical relevance, since its supposed effect vanishes at the
end of the dosing interval, just as it is supposed to start being
important. The PAEs of antibiotics exceeding the dosing in-
terval could still be of relevance. The PAE determined in vivo
is possibly, for the major part, a description of a sub-MIC effect
that is further influenced by environmental circumstances in
vivo. This in itself is clinically relevant, since it describes the
regrowth of bacteria during therapy. The PA-SME thus rep-
resents only the regrowth inhibition found when the antibiotic
concentration falls below the MIC.
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